For the quarter ended June 2024, 10x Genomics (TXG Quick QuoteTXG - Free Report) reported revenue of $153.1 million, up 4.3% over the same period last year. EPS came in at -$0.32, compared to -$0.53 in the year-ago quarter.

The reported revenue represents a surprise of +1.46% over the Zacks Consensus Estimate of $150.9 million. With the consensus EPS estimate being -$0.47, the EPS surprise was +31.91%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how 10x Genomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Consumables

  : $123.36 million versus the two-analyst average estimate of $119.63 million. The reported number represents a year-over-year change of +9.7%.

• Revenues- Services

  : $5.89 million versus the two-analyst average estimate of $5.51 million. The reported number represents a year-over-year change of +74.5%.

• Revenues- Instruments

  : $23.85 million versus the two-analyst average estimate of $26.28 million. The reported number represents a year-over-year change of -23%.

View all Key Company Metrics for 10x Genomics here>>>

Shares of 10x Genomics have returned +15.4% over the past month versus the Zacks S&P 500 composite's -6.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.